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Diabetic nephropathy is now the lead-ing cause of end-stage renal disease (ESRD) in the Western world, yet the genetic and environmental factors con-
tributing to its development remain elusive. Hence 
the search for such factors is one of the highest 
priorities in renal research, and, needless to say, 
we hope that papers that succeed in identifying 
them will be submitted to Kidney International. 
Genetic studies of diabetic populations have iden-
tified some potential risk factors, but none of them 
are sufficient to predict the development of pro-
gressive nephropathy in the diabetic population 
(for example, Iyengar et al.1). The identification of 
suitable animal models is considered a top priority 
by the US National Institutes of Health, which cre-
ated the Animal Models of Diabetic Complications 
Consortium (AMDCC) in 2001. The consortium 
is composed of epidemiologists, geneticists, clini-
cal researchers, and basic scientists and focuses on 
mouse models, as the mouse remains the primary 
mammalian model for disease analysis. Their first 
report delineated the various mouse models and 
their limitations.2 A follow-up report now identi-
fies progress and problems in methodology, mouse 
strains, and genetics.3
We at Kidney International feel that the conclu-
sions of these reports have not yet had the desired 
impact on many investigations. Hence, the editors 
wish to emphasize the following issues for pro-
spective studies in this field. The criteria listed 
in the AMDCC report are prerequisites for suc-
cessful use of mouse models. The first principle 
to keep in mind is that none of the mouse models 
fully mimics human diabetic nephropathy, espe-
cially in regard to progression to ESRD. Through 
the concerted effort of the AMDCC researchers, 
several models that recapitulate at least parts of 
the human disease have been identified.2–5 How-
ever, for appropriate use of these models, we 
encourage investigators to rigorously adhere to 
experimental quality control criteria outlined in 
the AMDCC publications.2,3 Let me recapitulate 
these principles here:
Diabetic nephropathy in mice should include 
functional evaluations with the expectation of a 
50% decline in glomerular filtration rate and at 
least a tenfold increase in albuminuria as com-
pared with controls. The mice need to be matched 
for genetic background and for age and sex. 
Further, pathological examination should include 
evidence of advanced mesangial matrix expansion, 
preferably in combination with mesangiolysis 
and nodular sclerosis, a more than 50% thick-
ening of the glomerular basement membrane, 
some arteriolar hyalinosis, and—in advanced 
stages—evidence of tubulointerstitial fibrosis. I 
also emphasize that rigorous criteria need to be 
set up to evaluate the functional and pathological 
descriptions of the mice, including standardized 
staining methods for histopathology.
Appropriate mouse strains
While the above criteria are somewhat obvious 
for any investigation, I feel that the issue of the 
use of appropriate mouse strains is the one that 
needs more attention in every study of diabetic 
nephropathy. The importance of individual 
genetic factors for the development of diabetic 
nephropathy in humans is well recognized and 
is the subject of intense investigation. Unfortu-
nately, the importance of the genetic background 
in mouse models of diabetic renal disease (dif-
ferent strains, inbreeding versus outbreeding, 
undetermined mixed genetic background, and so 
on) has not been adequately considered in many 
publications. The AMDCC is to be congratulated 
for having clearly identified this problem.2–5 
Their publications provide details and sources of 
information about mouse strain susceptibility for 
specific lesions in either type 1 or type 2 diabetes 
and include the use of new mouse models of dia-
betic nephropathy in genetically modified mouse 
strains.2–5 The important finding to be stressed 
here is that not all pathological manifestations 
known to occur in human diabetic nephropa-
thy are present in different mouse models. The 
compiled information provides the details about 
which changes of diabetic nephropathy develop in 
which model. Unfortunately, the most widely used 
inbred mouse strain, C57BL/6, is almost resistant 
to the development of diabetic nephro pathy as 
defined by the AMDCC criteria, making any con-
clusion reached in many studies using this strain 
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somewhat suspect.2,3 The situation is made worse 
by the fact that many knockout mice are back-
crossed onto C57BL/6, and is made even more 
so by the fact that at least the initial backcrosses 
represent a genetically heterogeneous model. The 
problems and pitfalls of interpreting experimental 
results obtained in knockout mice with a mixed 
genetic background have been repeatedly pointed 
out during the past 15 years.6,7 The exact genetic 
background of the mutant mice should always be 
known, and the mutant mouse lines should be 
maintained as congenic lines by consistent back-
crossing onto defined inbred backgrounds. Main-
taining mutant mice by inbreeding homozygous 
mice should be avoided, as random segregation 
often develops following consecutive backcross-
ing, leading to progressive and unpredictable 
changes in the genotype of the hybrid lines. Only 
if the same genetic background is used in experi-
ments can the differences between the phenotypes 
obtained be ascribed to the mutations rather than 
to different genetic backgrounds.
Unfortunately, it is extremely time consuming 
and costly to fully backcross mice into a suitable 
strain. Potential ways to deal with this problem 
have been pointed out.6,7 The importance of even 
small genetic admixtures from other strains is 
dramatically illustrated by the difference in the 
susceptibility to the development of diabetic 
renal disease in db/db type 2 diabetic mice in the 
C57BL/6 strain versus the C57BLKS strain.2,3 
The C57BLKS strain was originally derived from 
C57BL/6 and shares 84% of alleles with C57BL/6.8 
During the breeding of the C57BLKS strain, a con-
tamination with DBA/2J must have occurred, so 
that 16% of alleles are shared with DBA/2J. Even 
though both strains are now fully backcrossed, the 
small admixture of DBA/2J alleles is sufficient to 
render the C57BLKS mice susceptible to the devel-
opment of diabetic nephropathy, while C57BL/6 
mice are resistant. Potentially these differences 
could be used to advantage in order to identify 
either susceptibility genes for diabetic renal dis-
ease, perhaps present in the 16% allele admixture 
of DBA/J2 origin, or resistance genes present in 
the C57BL/6 genome.
I emphasize that even mouse strains suscepti-
ble to the development of some functional and 
pathological changes of diabetic nephropathy 
never exhibit the full range of pathology observed 
in human disease. This is especially true for the 
progressive development of renal insufficiency 
leading to ESRD, which is not seen in the mouse 
models. In order to broaden the spectrum and 
the severity of renal involvement in diabetic 
mice, various breeding and genetic modification 
schemes have been used. These are also detailed in 
the publications from the AMDCC and its mem-
bers.2–5 Targeted mutagenesis in the mouse has 
provided us with an enormously powerful tool 
to analyze the contribution of individual genes in 
physiology and disease and has thereby revolu-
tionized experimental biology. At present the most 
promising models for genetic eliminations favor-
ing diabetic nephropathy include the combination 
of either type 1 or type 2 diabetes mellitus with the 
genetic deletion of endothelial nitric oxide syn-
thase (eNOS),9–11 or the bradykinin 2 receptor.12 
Other potential genetically manipulated mouse 
models are listed in the latest AMDCC report.3
In summary, the publications from the AMDCC 
provide a superb compilation of the various mouse 
models and their advantages, problems, and 
potential pitfalls. The findings summarized in 
these publications should serve as quasi-guidelines 
for researchers in their planning of mouse experi-
ments on diabetic nephropathy and for review-
ers and editors in the evaluation of manuscripts 
resulting from such investigations.
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